Kodiak Sciences (NASDAQ:KOD), Inc. is a clinical‐stage biopharmaceutical company headquartered in Palo Alto, California, that focuses on the discovery and development of novel therapies for retinal diseases. The company’s proprietary technology centers on antibody biopolymer conjugates (ABCs), which are designed to extend durability, enhance tissue penetration and improve the safety profile of existing therapeutic modalities. Kodiak’s research and development efforts target conditions such as wet age-related macular degeneration (wet AMD), diabetic macular edema (DME) and other serious ophthalmic disorders.
The lead product candidate in Kodiak’s pipeline is KSI-301, an anti-VEGF antibody biopolymer conjugate administered via intravitreal injection. KSI-301 is engineered to achieve extended drug exposure in retinal tissue, with the goal of reducing treatment burden for patients by prolonging the interval between dosing. In addition to KSI-301, the company is advancing KSI-501, an anti-IL-6 receptor bioconjugate, which is being evaluated for its potential to address both VEGF-mediated and inflammatory pathways in retinal disease.
Founded in 2015 under the name Oligome and rebranded as Kodiak Sciences in 2017, the company completed its initial public offering on the Nasdaq in mid-2017. Kodiak has since built a team of experienced drug developers, regulatory specialists and clinicians to support its clinical programs. Robert R. Burke serves as President and Chief Executive Officer, bringing over two decades of leadership in biotechnology and pharmaceutical research to guide the company’s strategic direction.
Kodiak Sciences conducts its clinical trials primarily in the United States, with select international sites to support global patient enrollment. The company maintains collaborations and partnerships to bolster its research efforts and aims to establish long-term value through the advancement of its ABC platform. Kodiak continues to expand its clinical and regulatory capabilities as it moves toward pivotal studies and potential regulatory filings for its lead candidates.
